



NEW THERAPEUTICS FOR AGING DISEASES

[Press release](#)

BIOPHYTIS strengthens its senior management team

Philippe Dupont joined the Company as Chief Operating Officer

Romainville (France), July 30, 2015 – BIOPHYTIS (Alternext Paris: ALBPS), a biotech company specialized in the development of drug candidates to treat the aging diseases, today announced the nomination of Philippe Dupont as Chief Operating Officer in order to better support the company's expansion plans.

Philippe Dupont began his career within the pharmaceutical group Lavipharm before joining Opodex Industrie as a pharmacist, purchasing manager. More recently, he was the COO of Novagali Pharma (Santen group) where he managed the marketing of the medical devices and the Regulatory Affairs. Philippe Dupont holds a Phd in pharmacy (Paris XI University) completed by an Executive-MBA from ESSEC.

Stanislas Veillet, CEO of BIOPHYTIS, said: *"We are very pleased to welcome Philippe in our team. His solid expertise in pharma industry within operational functions and more recently in a listed biotech company specialized in ophthalmology constitute key assets for the development of BIOPHYTIS. As our COO, Philippe will coordinate our projects and he will manage the regulatory studies of toxicology and pharmacology as well as production of our candidates, as BIOPHYTIS is launching two phase 2b clinical studies in sarcopenic obesity (BIO101) and ARMD (BIO201)".*

About BIOPHYTIS:

BIOPHYTIS is a biotech company founded in 2006 and specialized in aging diseases. It develops innovative therapeutic solutions on pathologies, without treatment, in order to restore the muscular and visual functions.

BIOPHYTIS focuses its R&D efforts in the fight against the age-related macular degeneration (AMD) and the age-related muscular dystrophy (Sarcopenia). On these two highly invalidating diseases, the company has proprietary candidates entering in phase 2b.

Installed in the Biocitech technopark (Romainville-Paris), BIOPHYTIS has also a subsidiary in Brazil (Sao Paulo). The company is based on leading research collaborations with the UPMC (Pierre et Marie Curie University), the ICAN (Institute of Cardiometabolism and Nutrition), the Institute of Myologie and the Vision Institute.

For more information, please visit: www.biophytis.com

BIOPHYTIS is eligible for the French PEA-PME regime



Contacts :

BIOPHYTIS

Stanislas VEILLET

CEO

contact@biophytis.com

Tel : +33 (0) 1 41 83 66 00

Milestones – Press & Investors relations

Bruno ARABIAN

barabian@milestones.fr

Tel : +33 (0) 1 83 62 34 84 / +33 (0) 6 87 88 47 26